In our study, ICI combination therapy resulted in PFS of 10.3 months and OS of 41.6 months in NSCLC patients carrying EGFR mutations and PD-L1 TPS ≥ 50% after developing EGFR-TKI resistance without T790M mutations. This evidence concerns the gene CD274 and non-small cell lung carcinoma.